Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
15 mars 2021 07h39 HE
|
Rubius Therapeutics
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells into...
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
10 mars 2021 16h30 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Global Regenerative Medicine Partnering Deals, Terms and Agreements Directory 2014-2020: Analysis of the Structure of Regenerative Medicine Agreements with Real Life Case studies
12 févr. 2021 04h58 HE
|
Research and Markets
Dublin, Feb. 12, 2021 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering. The Global...
Global Regenerative Medicine Partnering Terms and Agreements 2014-2020: Company A-Z, Headline Value, Stage of Development, Deal component, Specific Therapy Target, Technology Type
24 sept. 2020 05h04 HE
|
Research and Markets
Dublin, Sept. 24, 2020 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering. The Global...
Worldwide Cell Therapy Industry to 2025 - North America is Leading the Cell Therapy Market
07 sept. 2020 05h38 HE
|
Research and Markets
Dublin, Sept. 07, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The cell therapy market...
Cord Blood Banking Leader Cryo-Cell Enters into Patent Option Agreement with Duke University
11 juin 2020 16h10 HE
|
Cryo-Cell International, Inc.
OLDSMAR, Fla., June 11, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store...
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting
12 mai 2020 06h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Multiverse Investment Fund Announces Portfolio Company’s Commencement of Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19)
15 avr. 2020 08h30 HE
|
Multiverse Investment Fund I, LP
Multiverse Investment Fund Portfolio Company Begins Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19) ARDS has been identified as the leading cause...
PharmaCyte Biotech Will Have All the Protection It Needs for Pancreatic Cancer Treatment Upon Marketing Approval
04 févr. 2020 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is about to embark upon a planned U.S. FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic...
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
30 janv. 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...